TY - JOUR
T1 - A combination study design to examine mycophenolate mofetil (MMF) and PTLD in renal transplant patients
AU - Kremers, Hilal Maradit
AU - Funch, Donnie P.
AU - Robson, Richard A.
AU - Nalesnik, Michael A.
AU - Ebrahim, Shah
AU - Cecka, Michael J.
AU - Opelz, Gerhard
AU - Dreyer, Nancy A.
AU - Walker, Alexander M.
PY - 1999/12
Y1 - 1999/12
N2 - Renal transplant recipients who are chronically immunosuppressed by drugs are at a higher risk of developing malignancies. Commonly observed malignancies are several forms of posttransplant lymphoproliferative disorders (PTLD), skin, lip and gynaecological cancers. The risk is associated with many risk factors including the extent of immunosuppression. Mycophenolate mofetil (MMF) is an immunosuppressant, indicated for the prophylaxis of organ rejection in patients receiving allogenic renal and heart transplants. During the European approval of MMF for renal transplantation, the question was raised as to whether the use of MMF was associated with an increased risk of PTLD in comparison with alternate immunosuppressive regimens. In response, F. Hoffman-La Roche Ltd set up a prospective observational cohort study with a companion case-control study. This paper describes the objectives and the methods of these studies along with the rationale of the methodology. Copyright (C) 1999 John Wiley and Sons, Ltd.
AB - Renal transplant recipients who are chronically immunosuppressed by drugs are at a higher risk of developing malignancies. Commonly observed malignancies are several forms of posttransplant lymphoproliferative disorders (PTLD), skin, lip and gynaecological cancers. The risk is associated with many risk factors including the extent of immunosuppression. Mycophenolate mofetil (MMF) is an immunosuppressant, indicated for the prophylaxis of organ rejection in patients receiving allogenic renal and heart transplants. During the European approval of MMF for renal transplantation, the question was raised as to whether the use of MMF was associated with an increased risk of PTLD in comparison with alternate immunosuppressive regimens. In response, F. Hoffman-La Roche Ltd set up a prospective observational cohort study with a companion case-control study. This paper describes the objectives and the methods of these studies along with the rationale of the methodology. Copyright (C) 1999 John Wiley and Sons, Ltd.
KW - Immunosuppression
KW - Mycophenolate mofetil
KW - PTLD
KW - Pharmacoepidemiology
KW - Posttransplant lymphoproliferative disorders
KW - Transplantation
UR - http://www.scopus.com/inward/record.url?scp=0033367137&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033367137&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1099-1557(199912)8:7<509::AID-PDS457>3.0.CO;2-1
DO - 10.1002/(SICI)1099-1557(199912)8:7<509::AID-PDS457>3.0.CO;2-1
M3 - Article
C2 - 15073894
AN - SCOPUS:0033367137
SN - 1053-8569
VL - 8
SP - 509
EP - 518
JO - Pharmacoepidemiology and Drug Safety
JF - Pharmacoepidemiology and Drug Safety
IS - 7
ER -